Pharmacognosy Research logo
Submit
Pharmacognosy ResearchACADEMIC PUBLISHING
Article

Targeting Breast Cancer with Triazine Derivatives: A Molecular Docking Analysis of Her2 and Parp1 Inhibition

1, 1, 1, 1, 2, 2, 3

  1. 1Department of Chemistry, School of Pharmacy, Sri Balaji Vidyapeeth (Deemed to be University), Pillayarkuppam, Pondicherry, INDIA.
  2. 2Department of Pharmacology, School of Pharmacy, Sri Balaji Vidyapeeth (Deemed to be University), Pillayarkuppam, Pondicherry, INDIA.
  3. 3Department of Pharmacognosy, School of Pharmacy, Sri Balaji Vidyapeeth (Deemed to be University), Pillayarkuppam, Pondicherry, INDIA.

CORRESPONDENCE

Mr. Thamizh Sendhamaraikannan

Department of Chemistry, School of Pharmacy, Sri Balaji Vidyapeeth (Deemed to be University), Pillayarkuppam, Pondicherry, INDIA.

thamizhs@sbvu.ac.in

Received: 19-05-2025; Accepted: 29-08-2025.

Volume 17, Issue 4 · pp. 1281-1292 · 2025 · DOI: 10.5530/pres.20252332

ABSTRACT

Background: Heterocyclic compounds, particularly triazines, have significant attention in pharmaceutical and industrial research due to their broad spectrum of biological activities.Objective: This study focuses on the synthesis and molecular docking analysis of 15 novel triazine derivatives (TCT1-TCT15) to evaluate their potential as inhibitors of two critical cancer-related targets: human epidermal growth factor receptor 2 (HER2) and poly (ADP-ribose) polymerase 1 (PARP1).Materials and Methods: The derivatives were synthesized by reacting 2,4,6-Trichloro- 1,3,5-Triazine (TCT) with various aldehydes, thereby incorporating diverse substituent groups. Molecular docking was conducted using AutoDock 1.5.5, and protein-ligand interactions were visualized through Chimera software.Results: The docking results revealed strong binding affinities of the synthesized compounds to both HER2 and PARP1. For HER2, TCT9 (-12.73 kcal/ mol), TCT4 (-12.47 kcal/mol), and TCT5 (-12.34 kcal/mol) showed the most favorable binding energies, all with inhibition constants in the nanomolar range. For PARP1, TCT13 (-13.96 kcal/ mol), TCT12 (-13.64 kcal/mol), and TCT4 (-13.33 kcal/mol) demonstrated superior binding interactions, surpassing those of standard inhibitors. Structural analysis indicated that the presence of electron-withdrawing groups such as -Cl and -NO₂, as well as electron-donating groups like -OH and -OCH₃, significantly influenced the binding efficacy of the compounds. Stabilization of the protein-ligand complexes was primarily mediated by hydrogen bonding and hydrophobic interactions.Conclusion: These findings suggest that the synthesized triazine derivatives, particularly TCT9, TCT13, and TCT4, exhibit strong potential as anticancer agents, warranting further in vitro and in vivo investigations to explore their clinical applicability.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    Sendhamaraikannan, T., Arivukkarasu, N. K., Sakthivel, E., Seevagavazhuthi, A., Natarajan, V., Devarasu, P., & Velmurugan, A. (2025). Targeting Breast Cancer with Triazine Derivatives: A Molecular Docking Analysis of Her2 and Parp1 Inhibition. Pharmacognosy Research, 17(4), 1281-1292. https://doi.org/10.5530/pres.20252332

    Copyright and licence

    © 2025 Author(s)

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. CC BY-NC-SA 4.0